Active-ingredient Dossier
Cabazitaxel
Active-ingredient Dossier for Cabazitaxel (microtubule stabilizing agent). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: CABAZITAXEL
- Brand: CABAZITAXEL
- Brand: CABAZITAXEL EVER PHARMA
- Brand: CABAZITAXEL-DRLA
- Brand: MSN
- Brand: CABAZITAXEL-REDDY'S
- Therapeutic area: Oncology
What is
Cabazitaxel Cabazitaxel is a microtubule stabilizing agent.
Australian brands containing
Cabazitaxel — CABAZITAXEL — CABAZITAXEL EVER PHARMA — CABAZITAXEL-DRLA — MSN — CABAZITAXEL-REDDY'S
Therapeutic areas
Cabazitaxel is registered in oncology, with 6 brands containing the ingredient.
Sponsor landscape
Four sponsors market cabazitaxel in Australia: Dr Reddys Laboratories, Accord Healthcare, Interpharma, and Reach Pharmaceuticals.
PBS and regulatory activity
One brand containing cabazitaxel has PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome on record is from 1 March 2022, with three brands having PBAC outcomes documented.